The massive registration of 44.2% of shares outstanding creates severe overhang risk. Monitor for selling stockholder filings (Form 144) and any 424B prospectus supplements indicating actual sales. The company's cash burn and lack of pipeline make further dilutive financing likely, compounding the overhang.
Price Chart
Executive Summary
Indaptus Therapeutics filed an S-3 registration statement to register 58,895,000 shares of common stock for resale by selling stockholders, representing ~44.2% of shares outstanding. The company has no active clinical programs, having discontinued its Decoy20 study, and is evaluating strategic alternatives. The filing itself raises no new capital for the company but creates massive potential overhang from the selling stockholders, who can sell into the market at any time.
Key Facts
- Registers 58,895,000 shares for resale by selling stockholders, representing ~44.2% of 133,242,324 shares outstanding.
- No new capital raised for the company; all proceeds go to selling stockholders.
- Company has discontinued all clinical programs (Decoy20) and has no active development pipeline.
- Auditor's report includes a going concern explanatory paragraph.
- Sino Lion Ventures Limited, a 29.19% holder, is registering 38,895,000 shares from converted preferred stock.
- Seven other non-U.S. investors are registering 20,000,000 shares from a June 2026 private placement at $0.60/share.
- Stock closed at $1.07 on August 14, 2026, the last trading day before filing.
Financial Impact
Potential overhang of ~$63M at $1.07/share from 58.9M registered shares, representing 44.2% of outstanding shares. The company's cash and short-term investments totaled $11.6M as of June 30, 2026.
Risk Factors
- Massive share overhang from 58.9M registered shares could crush the stock price if selling stockholders begin selling.
- Company has no active clinical programs and is burning cash with a going concern warning.
- Further dilutive financing is likely given the company's cash position and lack of revenue.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 7 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| S-3 Filing (Primary) | 0001493152-26-038780 |
| Exhibit: ex107.htm | 0001493152-26-038780 |
| Exhibit: ex5-1.htm | 0001493152-26-038780 |
| Exhibit: ex23-2.htm | 0001493152-26-038780 |
| Document: 0001493152-26-038780-index-headers.html | 0001493152-26-038780 |
| Document: 0001493152-26-038780-index.html | 0001493152-26-038780 |
| Document: 0001493152-26-038780.txt | 0001493152-26-038780 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 10, 2026 22d ago | 8-K | $2.56 $3.93 | ▼ −53.52% | ▼ −52.89% | $2.33 (+8.98%) |
Sep 4, 2026 27d ago | 424B5 | $1.85 $3.64 | ▼ −96.76% | ▼ −97.88% | $2.33 (−25.95%) |
Sep 1, 2026 4w ago | 8-K | $1.13 $2.08 | ▼ −84.07% | ▼ −83.99% | $2.33 (−106.19%) |
Aug 26, 2026 5w ago | EFFECT | $1.14 $1.17 | ▼ −2.63% | ▼ −2.75% | $2.33 (−104.39%) |
Aug 17, 2026 6w ago | S-3 | $0.9361 $1.10 | ▼ −16.97% | ▼ −17.18% | $2.33 (−148.91%) |
Aug 13, 2026 7w ago | 8-K | $1.06 $1.38 | ▲ +30.19% | ▲ +32.15% | $2.33 (+119.81%) |
Jul 20, 2026 10w ago | EFFECT | $2.46 $2.61 | ▼ −6.10% | ▼ −6.52% | $2.33 (+5.28%) |
Jun 26, 2026 13w ago | S-3 | $3.06 $2.85 | ▲ +6.86% | ▲ +8.25% | $2.33 (+23.86%) |
Jun 24, 2026 14w ago | 8-K | $3.26 $2.94 | ▲ +9.82% | ▲ +11.38% | $2.33 (+28.53%) |
May 15, 2026 20w ago | 8-K | $1.59 $1.22 | ▲ +23.27% | ▲ +24.23% | $2.33 (−46.54%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access